Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020

Rhea-AI Summary

Advaxis, Inc. (Nasdaq: ADXS) announced its participation at the 35th Annual Meeting of the Society for Immunology of Cancer (SITC 2020), presenting an ePoster on November 12th and 14th. The presentation will focus on a Phase 1/2 study of ADXS-503, a multi-neoantigen vector, alone and with Pembrolizumab in metastatic non-small cell lung cancer (NSCLC). This innovative immunotherapy product utilizes bioengineered Listeria monocytogenes to stimulate anti-tumor T cell immunity. For more details, the poster will be accessible on Advaxis' website.

Positive

• Presentation of significant clinical study results at SITC 2020.
• Focus on an innovative treatment approach for metastatic NSCLC.
• Engagement with scientific community through ePoster.

Negative

• None.

PRINCETON, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it will present an ePoster at the 35^th Annual Meeting of the Society for Immunology of Cancer (SITC 2020) to be held virtually November 9-14, 2020.

Title: “Phase 1/2 Study of an Off-the-Shelf, Multi-Neoantigen Vector (ADXS-503) Alone and in Combination with Pembrolizumab in Subjects with Metastatic Non-Small Cell Lung Cancer (NSCLC)”
Presenter: Dr. Jonathan W. Goldman. University of California Los Angeles, Santa Monica, CA
Abstract ID: 360
Date and Time: Thursday, November 12^th from 4:50 pm until 5:20 pm ET and Saturday, November 14^th from 1:00 pm until 1:30 pm ET.

The poster will be available on Advaxis’ website at https://www.advaxis.com/events-and-presentations

About Advaxis, Inc.
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.

Investor Contact
Tim McCarthy
LifeSci Advisors, LLC
Tim@lifesciadvisors.com
(212) 915-2564

FAQ

What is the focus of Advaxis' ePoster at SITC 2020?

Advaxis is presenting a Phase 1/2 study of ADXS-503, a multi-neoantigen vector, in combination with Pembrolizumab for metastatic non-small cell lung cancer.

When will Advaxis present their ePoster?

Advaxis will present the ePoster on November 12th and November 14th, 2020.

What is ADXS-503?

ADXS-503 is an off-the-shelf, multi-neoantigen vector aimed at stimulating anti-tumor immunity in metastatic NSCLC patients.

How does Advaxis' therapy work?

The therapy uses bioengineered Listeria monocytogenes to enhance immune response against tumors.

Where can I find the ePoster presented by Advaxis?

The ePoster will be available on Advaxis' website during and after the conference.